Novartis

Title	Published Date
Commitment of Novartis in advancing treatments for patients with cancer and rare diseases	02 December 2010
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment	18 November 2010
New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate	04 November 2010
Novartis drug Afinitor® approved by FDA	31 October 2010
Novartis delivers excellent performance in third quarter	22 October 2010
Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis	19 October 2010
Novartis affirms commitment to sustain efforts toward final elimination of leprosy	13 October 2010
Novartis discontinues development of two investigational compounds	06 October 2010
Novartis sells US rights to the overactive bladder treatment Enablex®	28 September 2010
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment	23 September 2010

Didn't we got you connected? If not, please note the following magic buttons:
Facebook
Twitter
LinkedIn
RSS